Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.73 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.73 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.73 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone SCHEMBL23390 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL14577661 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL19510084 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL14074493 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL7768886 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL24476231 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL6834811 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11781372 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL9161897 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11291575 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNACYP2C19ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023068376-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | 国立大学法人九州大学 | 2023-04-27 | — | — | WO | disclosed |
| EP-3345594-B1 | SOLUBILIZED FLAVONOID COMPOSITION | TECH INVESTMENTS LC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3345594-A1 | SOLUBILIZED FLAVONOID COMPOSITION | Vizuri Health Sciences LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2012054090-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS | API GENESIS, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | PGR 1258/4885CYP3A4 14/4885LMNA 3422/4885 |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | PGR 1258/4885CYP3A4 14/4885LMNA 3422/4885 |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | PGR 1258/4885CYP3A4 14/4885LMNA 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.